Business Context and Reporting Period
This Form 8-K, dated April 28, 2022, reports on Zimmer Biomet Holdings, Inc. (ZBH) following the completion of the separation of its spine and dental businesses into a new entity, ZimVie Inc., on March 1, 2022. The distribution occurred on February 15, 2022, at a ratio of one ZimVie share for every ten ZBH shares. The filing provides unaudited recast financial information to reflect these businesses as discontinued operations, effective for the Form 10-Q period ending March 31, 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1, which contains the unaudited consolidated statements of earnings recast to exclude the discontinued spine and dental operations. The document focuses on the structural changes to financial reporting rather than presenting a full set of financial results.
Material Changes Versus Prior Period
- Discontinued Operations: Historical results for the spine and dental businesses are being recast to exclude them from net sales and expenses, classifying them as discontinued operations.
- Non-GAAP Adjustments: The Company is revising its non-GAAP financial measures to include upfront charges and development milestones related to in-process research and development (IPR&D) projects acquired in transactions other than business combinations. Previously, these material charges were excluded.
- Regulatory Driver: The change in non-GAAP treatment is due to recent guidance from the U.S. Securities and Exchange Commission.
Guidance, Outlook, and Risks
The Company intends to apply the new non-GAAP financial measure adjustments beginning with the press release for the quarter ended March 31, 2022. The recast financial information is for informational purposes only and does not necessarily reflect results that would have been reported had the separation occurred earlier, nor is it indicative of future results. The filing includes standard forward-looking statement disclaimers regarding risks, uncertainties, and the quarter-end closing process.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited recast historical financial information.
- Verify the impact of the new non-GAAP adjustments on earnings per share in the upcoming Q1 2022 earnings release.
- Confirm the treatment of IPR&D charges in future non-GAAP reconciliations.
- Monitor the Company's Form 10-Q for the period ended March 31, 2022, for the official adoption of discontinued operations reporting.